| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/30/2006 | WO2006034089A1 Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity |
| 03/30/2006 | WO2006034085A1 Crystalline form of atrasentan hydrochloride |
| 03/30/2006 | WO2006034084A1 Crystalline form 2 of atrasentan hydrochloride |
| 03/30/2006 | WO2006034080A2 Formulation comprising itraconazole |
| 03/30/2006 | WO2006034048A2 Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 03/30/2006 | WO2006034039A2 Substituted morphinans and methods of their use |
| 03/30/2006 | WO2006034016A1 (arylamidoanilino) nitroethylene compounds |
| 03/30/2006 | WO2006034015A1 (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
| 03/30/2006 | WO2006034006A1 Polymorphs of the cysteine protease inhibitor n- (1-cyanocyclopropyl)-3-cyclopropylmethansulfonyl-2 (r) - (2,2,2-trifluoro-1 (s) - (4-fluorophenyl) ethylamino) propionamide |
| 03/30/2006 | WO2006034003A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity |
| 03/30/2006 | WO2006034001A2 Methods of treating hiv infection |
| 03/30/2006 | WO2006033979A1 Treatment of androgen - deprivation induced osteoporosis |
| 03/30/2006 | WO2006033965A2 Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
| 03/30/2006 | WO2006033948A2 Sustained local anesthetic composition containing preferably a sugar ester such as saib |
| 03/30/2006 | WO2006033943A2 Pyrazole kinase modulators and methods of use |
| 03/30/2006 | WO2006033913A2 Bis (thio-hydrazide amides) for treament of hyperplasia |
| 03/30/2006 | WO2006033907A2 Methods of treating disorders having a component of mercury toxicity |
| 03/30/2006 | WO2006033891A2 Compounds for the treatment of dyslipidemia and other lipid disorders |
| 03/30/2006 | WO2006033848A1 Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 03/30/2006 | WO2006033844A2 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide kcnq potassium channel modulators |
| 03/30/2006 | WO2006033796A1 SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME |
| 03/30/2006 | WO2006033795A2 Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| 03/30/2006 | WO2006033734A2 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| 03/30/2006 | WO2006033703A1 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
| 03/30/2006 | WO2006033698A2 Tissue matrix system |
| 03/30/2006 | WO2006033693A2 Methods of selectively treating diseases with specific glycosaminoglycan polymers |
| 03/30/2006 | WO2006033631A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i |
| 03/30/2006 | WO2006033630A1 Compounds, compositions containing them, preparation thereof and uses thereof iii |
| 03/30/2006 | WO2006033627A1 Compounds, compositions containing them, preparation thereof and uses thereof iiii |
| 03/30/2006 | WO2006033620A1 New heterocyclic amides |
| 03/30/2006 | WO2006033568A1 Synergistic composition for the treatment of diabetes and the comorbidites thereof |
| 03/30/2006 | WO2006033453A1 Activity enhancer for interferon agent |
| 03/30/2006 | WO2006033422A1 Quinolizinone compound and use thereof as hiv integrase inhibitor |
| 03/30/2006 | WO2006033412A1 Alleviator for radiation disorder |
| 03/30/2006 | WO2006033355A1 Oral pharmaceutical for dry skin prevention or remedy |
| 03/30/2006 | WO2006033349A1 Total enteral nutritious composition |
| 03/30/2006 | WO2006033343A1 Composition for prevention or alleviation of pigmentation |
| 03/30/2006 | WO2006033296A1 Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
| 03/30/2006 | WO2006033287A1 PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE |
| 03/30/2006 | WO2006033081A2 Peroxisome proliferation receptor agonists, for the treatment of gastritis |
| 03/30/2006 | WO2006033007A2 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| 03/30/2006 | WO2006033006A2 Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
| 03/30/2006 | WO2006033004A1 Quinoline compounds as cetp inhibitors |
| 03/30/2006 | WO2006033002A1 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| 03/30/2006 | WO2006033001A1 Quinoline compounds |
| 03/30/2006 | WO2006033000A2 N-ethyl hydroxyethylamine useful in treating cns conditions |
| 03/30/2006 | WO2006032999A1 N-methyl hydroxyethylamine useful in treating cns conditions |
| 03/30/2006 | WO2006032987A1 Indoline compounds and their use in the treatment of arteriosclerosis |
| 03/30/2006 | WO2006032959A2 Processes for the preparation of pyrrole derivatives |
| 03/30/2006 | WO2006032921A1 Bioreductively-activated prodrugs |
| 03/30/2006 | WO2006032908A1 Bioreductively-activated prodrugs |
| 03/30/2006 | WO2006032885A2 2-substituted estrogen sulphamates for inhibition of steroid sulphatase |
| 03/30/2006 | WO2006032869A1 Dna-pk inhibitors |
| 03/30/2006 | WO2006032771A1 Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof |
| 03/30/2006 | WO2006032717A1 Additive for culture fish feed and feed containing said additive for the treatment and prevention of oxidative stress and toxicity from parasiticide treatments |
| 03/30/2006 | WO2006032675A1 Aqueous pharmaceutical preparation comprising roflumilast |
| 03/30/2006 | WO2006032631A1 Inhibitors of the interaction between mdm2 and p53 |
| 03/30/2006 | WO2006032624A1 Pharmaceutical composition for transdermal administration |
| 03/30/2006 | WO2006032541A1 Indol derivatives as inhibitors of soluble adenylyl cyclase |
| 03/30/2006 | WO2006032537A2 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 03/30/2006 | WO2006032520A1 Oxazole derivatives as her tyrosine kinase inhibitors |
| 03/30/2006 | WO2006032519A1 Tricycles, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | WO2006032509A1 Indole derivatives, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | WO2006032481A1 Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain |
| 03/30/2006 | WO2006032461A1 Stable dosing form of phenylalanine derivatives |
| 03/30/2006 | WO2006032459A1 Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain |
| 03/30/2006 | WO2006032453A1 1,2,3 -triazole derivatives as receptor tyrosine kinase inhitors |
| 03/30/2006 | WO2006032386A1 Lyophilisate containing n-diaminomethylene-2-methyl-4,5-di-(methylsulfonyl)-benzamide |
| 03/30/2006 | WO2006032380A1 Quaternary alkaloid derivatives of chelidonium majus l |
| 03/30/2006 | WO2006032372A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, their use as a medicament, and a medicament containing them |
| 03/30/2006 | WO2006032342A2 Carbonyl compound-containing drug and the use thereof |
| 03/30/2006 | WO2006032330A1 Annexin modulation and resistance to infection |
| 03/30/2006 | WO2006032273A1 2-acylaminothiazole derivatives |
| 03/30/2006 | WO2006032144A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources |
| 03/30/2006 | WO2006032143A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| 03/30/2006 | WO2006032122A1 An antioxidant complex and a cosmetic and pharmaceutical composition comprising said complex |
| 03/30/2006 | WO2006032115A2 Composition against cardiovascular diseases |
| 03/30/2006 | WO2006032089A1 Sustained release pharmaceutical composition |
| 03/30/2006 | WO2006032086A1 Chroman derivatives, medicaments and use in therapy |
| 03/30/2006 | WO2006032085A1 Substituted chroman derivatives, medicaments and use in therapy |
| 03/30/2006 | WO2006017566A9 Modulation of bio-electrical rhythms via a novel engineering approach |
| 03/30/2006 | WO2006017353A3 Treatment of viral infections |
| 03/30/2006 | WO2006014864A3 Methods and compositions for reducing c-reactive protein |
| 03/30/2006 | WO2006011024A3 New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 03/30/2006 | WO2006010560A8 Physiologically active composition |
| 03/30/2006 | WO2006010544A3 1, 1a, 5, 5a-tetrahydro-3-thia-cyclopropa’a! pentalenes: tricyclic thiophene derivatives as s1p1/edg1 receptor agonists |
| 03/30/2006 | WO2006008656A3 Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
| 03/30/2006 | WO2006008545A3 Thiazole and isothiazole derivatives as protein kinase inhibitors |
| 03/30/2006 | WO2006006691A3 Solid dispersion of a p38 map kinase inhibitor |
| 03/30/2006 | WO2006000912A3 Pyridyl piperazines for the treatment of cns disorders |
| 03/30/2006 | WO2005123736A8 Novel 2-benzylaminodihydropteridinones, method for producing them and use thereof as drugs |
| 03/30/2006 | WO2005123137A3 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride |
| 03/30/2006 | WO2005123132A3 Use of liver-selective glucokinase activators |
| 03/30/2006 | WO2005123089A3 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 03/30/2006 | WO2005123049A3 A pharmaceutical composition for increasing the mitochondrial genesis |
| 03/30/2006 | WO2005123048A3 Screening methods using c-abl, fyn and syk in combination with tau protein |
| 03/30/2006 | WO2005120643A3 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms |
| 03/30/2006 | WO2005120515A3 Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease |
| 03/30/2006 | WO2005117867A3 Monocyclic heterocycles as kinase inhibitors |
| 03/30/2006 | WO2005116028A3 Bicyclic heterocycles as kinase inhibitors |